Heidelberg-based Revier Therapeutics launches with €6 million to develop cardiometabolic therapies

HomeGermany-StartupsHeidelberg-based Revier Therapeutics launches with €6 million to develop cardiometabolic therapies FundingGermany-Startups Heidelberg-based Revier Therapeutics launches with €6 million to develop cardiometabolic therapies By Rahul Raj August 28, 2026 Share FacebookTwitterWhatsAppLinkedin Revier Therapeutics, a Heidelberg-based BioTech company advancing disease-modifying therapies for patients with cardiometabolic disease, has officially launched and announced the closing of a €6 million Seed financing round.  The round was led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. This sector-wide development has drawn attention from market participants. HomeGermany-StartupsHeidelberg-based Revier Therapeutics launches with €6 million to develop cardiometabolic therapies FundingGermany-Startups Heidelberg-based Revier Therapeutics launches with €6 million to develop cardiometabolic therapies By Rahul Raj August 28, 2026 Share FacebookTwitterWhatsAppLinkedin Revier Therapeutics, a Heidelberg-based BioTech company advancing disease-modifying therapies for patients with cardiometabolic disease, has officially launched and announced the closing of a €6 million Seed financing round.  The round was led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg.Eva van Rooij, PhD, co-founder and Chief Executive Officer of Revier Therapeutics, said, “Despite significant progress in cardiovascular medicine, millions of patients with HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease) still to date face limited targeted treatment options.We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology to deliver impactful and long-term solutions for patients.  “Our mission is to translate the scientific potential of class IIa HDAC inhibition into a pipeline of novel therapies and rapidly advance our lead programs toward the clinic to create long-term value for both patients and the broader healthcare ecosystem.” Revier Therapeutics has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.Key players involved: GI Partners This development has significant implications for the industry, potentially influencing competitive dynamics, investment patterns, and strategic priorities across the sector. HDACs are enzymes that play a functional role in a variety of severe diseases, the German startup explains. Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert CommentaryCombined with an exceptional leadership team and deep scientific expertise, the company has a unique opportunity to deliver disease-modifying medicines and reshape the standard of care by providing durable benefit for patients with HFpEF, ASCVD and related cardiometabolic disorders,” said Michael Hamacher, PhD, Managing Partner and CFO at KHAN Technology Transfer Fund II. Looking AheadFor complete details on this development, refer to the original report from EU-Startups. Frequently Asked Questions